Teva Pharmaceuticals Highlights Critical Treatment Gaps for Tardive Dyskinesia in Long-Term Care Facilities

A Teva Pharmaceuticals study reveals that over half of long-term care residents with tardive dyskinesia (TD) do not receive standard treatment, with a quarter left untreated, highlighting significant care gaps. The research indicates frequent misdiagnosis as extrapyramidal syndrome, leading to inappropriate treatments, as most patients receive non-FDA approved therapies. This underscores the need for improved awareness and intervention for TD in long-term care settings, potentially creating opportunities for companies like Teva that are focused on addressing these unmet medical needs.

Analysis

Teva Pharmaceuticals' recent study reveals a substantial unmet medical need in tardive dyskinesia (TD) treatment within long-term care (LTC) facilities, with over half of diagnosed residents not receiving standard of care and a quarter remaining untreated. The study, presented at Psych Congress Elevate on May 30, 2025, highlights prevalent misdiagnosis as extrapyramidal syndrome and reliance on non-FDA approved therapies, underscoring a critical gap Teva aims to address, potentially bolstering its leadership in neurological treatments. This strategic focus is supported by analyst sentiment from late 2024, including three "Buy" or "Overweight" ratings from firms like UBS and Barclays, with a median price target of $28.0. Institutional activity for $TEVA in Q1 2025 was mixed; while 258 institutional investors added shares, including significant purchases by Harel Insurance, Rubric Capital Management, and Goldman Sachs Group, 302 decreased their positions, and Arrowstreet Capital liquidated its entire holding. A notable counter-signal is the insider trading activity over the past six months, which exclusively comprised 18 sales by Teva insiders, including the President and CEO, totaling millions of dollars, with zero insider purchases recorded during this period. This pattern of insider divestment contrasts with the company's positive messaging regarding TD market opportunities and the bullish analyst ratings.

Key Decisions for Investors

• Consider the market opportunity Teva has identified in tardive dyskinesia treatment, which aligns with positive analyst ratings, but weigh this against the significant and consistent pattern of insider selling.
• Monitor Teva's execution in addressing the highlighted TD care gap, looking for tangible progress in research advancement, product uptake, and impact on revenue streams in subsequent financial reports.
• Investors should exercise caution due to the divergence between bullish external analyst outlooks and the bearish signal from substantial insider sales, and closely watch for shifts in institutional holdings in the upcoming quarters for further conviction.